| P50 | author | Iara F Kretzer | Q87427023 |
| P2093 | author name string | Aricio Treitinger | |
| | Celso Spada | |
| | Andrea do Livramento | |
| | Iraci Tosin | |
| | Joel da Cunha | |
| | Sabrina Gonçalves | |
| P2860 | cites work | Boceprevir for previously treated chronic HCV genotype 1 infection | Q24620576 |
| | Best strategies for global HCV eradication | Q27693824 |
| | Global epidemiology of hepatitis C virus infection | Q27860799 |
| | Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention | Q28286743 |
| | Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence | Q29616009 |
| | Telaprevir for retreatment of HCV infection | Q29619799 |
| | Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 |
| | The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 |
| | The global burden of hepatitis C | Q29620138 |
| | Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 |
| | A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt | Q30403548 |
| | Epidemiological profile of hepatitis C in blood donors at the Uberaba Regional Blood Center | Q33418392 |
| | Strategies to prevent and control hepatitis B and C virus infections: a global perspective | Q33589207 |
| | The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt | Q33884428 |
| | Epidemiology of hepatitis C virus (HCV) infection | Q33995067 |
| | EASL Clinical Practice Guidelines: management of hepatitis C virus infection | Q34168383 |
| | Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study | Q34572367 |
| | Gender influence on treatment of chronic hepatitis C genotype 1. | Q50559457 |
| | [The sustained response rates for chronic hepatitis C patients undergoing therapy with the several interferons and ribavarins supplied by Brazilians Health Ministry is comparable to those reported in the literature]. | Q50580363 |
| | Health conditions and health-policy innovations in Brazil: the way forward | Q56783487 |
| | [Seroprevalence of anti-hepatitis C virus antibodies among blood donors, Brazil] | Q78330268 |
| | [Seroprevalence of hepatitis B virus and hepatitis C virus infections among individuals in the State of Pará] | Q82287715 |
| | An Estimate of the Cost of Hepatitis C Treatment for the Brazilian Health System | Q88495586 |
| | Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting | Q34577107 |
| | Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa | Q34683612 |
| | Sexual activity as a risk factor for hepatitis C. | Q34984066 |
| | Epidemiology of hepatitis virus B and C. | Q36871379 |
| | Hepatitis C in India | Q37390227 |
| | Epidemiology of hepatitis B and C viruses: a global overview | Q37685594 |
| | Methodology of a nationwide cross-sectional survey of prevalence and epidemiological patterns of hepatitis A, B and C infection in Brazil | Q37793952 |
| | Trends and projections of hepatitis C virus epidemiology in Latin America. | Q37886279 |
| | A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel | Q37886280 |
| | New challenges in viral hepatitis. | Q38002785 |
| | Future therapies for chronic hepatitis C. | Q38082566 |
| | Prevalence of viral hepatitis B and C in riverside communities of the Tucuruí Dam, Pará, Brazil | Q38964457 |
| | Prevalence of hepatitis B and C serological markers among first-time blood donors in Brazil: a multi-center serosurvey | Q39294392 |
| | Seroprevalence of hepatitis B and hepatitis C markers among children and adolescents in the south Brazilian region: metropolitan area of Florianópolis, Santa Catarina | Q39930688 |
| | Using pegylated interferon alfa-2b and ribavirin to treat chronic hepatitis patients infected with hepatitis c virus genotype 1: are nonresponders and relapsers different populations? | Q42977073 |
| | A high prevalence of antibodies to hepatitis C virus among commercial plasma donors from Western India | Q42978122 |
| | Assessment of the treatment of chronic hepatitis C in the state of Mato Grosso, central Brazil | Q42978348 |
| | Global burden of hepatitis C: considerations for healthcare providers in the United States | Q42981508 |
| | The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1. | Q43030480 |
| | Seroprevalence of hepatitis B and C infection markers among children and adolescents in the southern Brazilian region | Q43035261 |
| | Detection of HIV-1, HBV and HCV antibodies in blood donors from Surat, western India | Q43036840 |
| | Seroprevalence of hepatitis B and hepatitis C markers in adolescents in Southern Brazil | Q43037024 |
| | Treatment of hepatitis C with peginterferon and ribavirin in a public health program. | Q44138387 |
| | Seroprevalence of hepatitis B and C virus markers among blood donors in Rio de Janeiro, Brazil, 1998-2005. | Q45020309 |
| | Seroepidemiological study on hepatitis C virus infection among blood donors from various regions in China | Q45173396 |
| | Acute hepatitis C in Brazil: results of a national survey | Q45176997 |
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| | RNA virus infectious disease | Q18967413 |
| | outbreak prevention | Q96043460 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 827849 | |
| P577 | publication date | 2014-06-10 | |
| P1433 | published in | The Scientific World Journal | Q7762585 |
| P1476 | title | Hepatitis C worldwide and in Brazil: silent epidemic--data on disease including incidence, transmission, prevention, and treatment. | |
| P478 | volume | 2014 | |